Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SCN4A | P35499 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL263971 | 0.98 | SCN10A (0.37) | SCN10AADRB2EIF4A3NPC1RAB9A | |
| SCHEMBL7968994 | 0.85 | SCN10A (0.43) | SCN10AEIF4A3NPC1RAB9AMEN1 | |
| Hydrochloric Acid SCHEMBL3932764 | 0.84 | ADRB2 (0.34) | SCN10AADRB2 | |
| SCHEMBL24481561 | 0.82 | SCN10A (0.32) | SCN10AEIF4A3 | |
| SCHEMBL502177 | 0.82 | SCN10A (0.32) | SCN10AEIF4A3 | |
| SCHEMBL265289 | 0.81 | SCN10A (0.41) | SCN10A | |
| SCHEMBL26999655 | 0.79 | SCN10A (0.48) | SCN10AMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL31229266 | 0.77 | PTGS2 (0.45) | MEN1MAPTKMT2A | |
| SCHEMBL25562963 | 0.72 | GPR84 (0.36) | SCN10A | |
| Benzotriazole SCHEMBL241937 | 0.72 | TAAR1 (0.40) | NPC1RAB9AMEN1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134004-B2 | Substituted N-bicyclicalkyl bicycliccarboxyamide compounds | PFIZER INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090253740-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253740-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS | OPRL1, CNR1, TRPV1 | SCN10A 131/4885ADRB2 281/4885EIF4A3 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.